Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension

Journal of Human Hypertension

Volumn 24, Issue 6, 2010, Pages 387-394

  Sato, A ^a   Fukuda, S ^a  

^a International University of Health and Welfare Mita Hospital   (Japan)

Author keywords

Aldosterone; Aldosterone blocker; Essential hypertension; Metabolic syndrome

Indexed keywords

ALBUMIN; ALDOSTERONE; ALDOSTERONE ANTAGONIST; AMLODIPINE; C REACTIVE PROTEIN; CREATININE; ELECTROLYTE; EPLERENONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMIDAPRIL; POTASSIUM; RENIN; TRIACYLGLYCEROL;

ADULT; ALBUMINURIA; ARTICLE; BIOCHEMISTRY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DIET THERAPY; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG SELECTIVITY; ESSENTIAL HYPERTENSION; EXERCISE; FEMALE; GINGIVITIS; HUMAN; JAPANESE; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MORNING DOSAGE; SOMNOLENCE; SYSTOLIC BLOOD PRESSURE; TASTE DISORDER; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; ALBUMINURIA; ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CALCIUM CHANNEL BLOCKERS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; JAPAN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RENIN; SPIRONOLACTONE; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 77952425215     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2009.81     Document Type: Article

References (44)

1. Funder JW. Aldosterone, salt and cardiac fibrosis. Clin Exp Hypertens 1997;19:885-899.
2. Young M, Fullerton M, Dilley R, Funder JW. Mineralocorticoids, hypertension and cardiac fibrosis. J Clin Invest 1994;93:2578-2583.
3. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium and myocardial fibrosis. J Lab Clin Med 1992;120:893-901.
4. Rocha R, Stier Jr CT, Kifor I, Ochoa-maya MR, Rennke HG, Williams GH et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000;141:3871-3878.
5. Sato A, Saruta T. Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status. Hypertens Res 2004;27:303-310.
6. Pitt B, Zannad F, Remme W, Cody R, Castaigne A, Perez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-717.
7. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321.
8. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003;41:64-68.
9. Sato A, Hayashi K, Saruta T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 2005;18:44-49.
10. Skluth HA, Gums JG. Spironolactone: a re-examination. DICP 1990;24:52-59.
11. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003;16:925-930.
12. Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007;49:839-845.
13. White WB, Carr AA, Krause S, Jordan R, Roniker B, Oigman W. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am J Hypertens 2003;92:38-42.
14. Williams GH, Burgess E, Kolloch RE, Ruilope LM, Niegowska J, Kipnes MS et al. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol 2004;93:990-996.
15. Flack JM, Oparil S, Pratt JH, Roniker B, Garthwaite S, Kleiman JH et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003;41:1148-1155.
16. Weinberger MH, White WB, Ruilope LM, MacDonald TM, Davidson RC, Roniker B et al. Effects of eplerenone versus losartan in patients with low-renin hypertension. Am Heart J 2005;150:426-433.
17. White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003;41:1021-1026.
18. Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mildto-moderate hypertension. Am J Hypertens 2002;15:709-716.
19. Krum H, Nolly H, Workman D, He W, Roniker B, Krause S et al. Efficacy of eplerenone added to reninangiotensin blockade in hypertensive patients. Hypertension 2002;40:117-123.
20. Burgess ED, Lacourciere Y, Ruilope-Urioste LM, Oparil S, Kleiman JH, Krause S et al. Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension. Clin Ther 2003;25:2388-2404.
21. Struthers A, Krum H, Williams GH. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol 2008;31:153-158.
22. Saruta T, Kageyama S, Ogihara T, Hiwata K, Ogawa M, Tawara K et al. Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, double-blind, placebo-control, dose-ranging study. J Clin Hypertens 2004;6:175-183.
23. Levy DG, Rocha R, Funder JW. Distinguishing the antihypertensive and electrolyte effects of eplerenone. J Clin Endocrinol Metab 2004;89:2736-2740.
24. Hillebrand U, Schillers H, Riethmuller C, Stock C, Wilhelmi M, Oberleithner H et al. Dose-dependent endothelial cell growth and stiffening by aldosterone: endothelial protection by eplerenone. J Hypertens 2007;25:639-647.
25. Sartorio CL, Fraccarollo D, Galuppo P, Leutke M, Ertl G, Stefanon I et al. Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction. Hypertension 2007;50:919-925.
26. Prisant LM, Krum H, Roniker B, Krause SL, Fakouhi K, He W. Can renin status predict the antihypertensive efficacy of eplerenone add-on therapy? J Clin Pharmacol 2003;43:1203-1210.
27. The Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension. Chapter 4. Lifestyle modification. Hypertens Res 2009;32:29-32.
28. Croom KF, Perry CM. Eplerenone. A review of its use in essential hypertension. Am J Cardiovasc Drugs 2005;5:51-69.
29. de Gasparo M, Joss U, Ramjoue HP, Whitebread SE, Haenni H, Schenkel L et al. Three new epoxyspironolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 1987;240:650-656.
30. Hu X, Li S, McMahon EG, Lala DS, Rudolph AE. Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone. Mini Rev Med Chem 2005;5:709-718.
31. Hollenberg NK, Williams GH, Anderson R, Akhras KS, Bittman RM, Krause SL. Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension. Arch Intern Med 2003;163:1543-1548.
32. Sato A, Saruta T, Funder JW. Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection. Hypertens Res 2006;29:211-216.
33. Kidambi S, Kotchen JM, Grim CE, Raff H, Mao J, Singh RJ et al. Association of adrenal steroid with hypertension and the metabolic syndrome in blacks. Hypertension 2007;49:704-711.
34. Colussi G, Catena C, Lapenna R, Nadalini E, Chiuch A, Sechi LA. Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care 2007;30:2349-2354.
35. Catena C, Lapenna R, Baroselli S, Nadalini E, Colussi G, Novello M et al. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endcrinol Metab 2006;91:3457-3463.
36. Fallo F, Veglio F, Bertello C, Sonino N, Mea PD, Ermani M et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endcrinol Metab 2006;91:454-459.
37. Goodfriend TL, Egan BM, Kelley DE. Aldosterone in obesity. Endcrine Res 1998;24:789-796.
38. Feldman D, Loose D. Glucocorticoid receptors and adipose tissue. Endocrinology 1977;100:398-405.
39. Morris DJ, Brem AS, Ge R, Jellinck PH, Sakai RR, Hardy MP. The functional roles of 11β-HSD1: vascular tissue, testis and brain. Mol Cell Endocrinol 2003;203:1-12.
40. Stewart PM, Toogood AA, Tomlinson JW. Growth hormone, insulin-like growth factor-1 and cortisolcortisone shuttle. Horm Res 2001;56:1-6.
41. Tallec LPL, Lombes M. The mineralocorticoid receptor: a journey exploring its diversity and specificity of action. Mol Endcrinol 2005;19:2211-2221.
42. Caprio M, Feve B, Claes A, Viengchareun S, Lombes M, Zennaro MC. Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J 2007;21:2185-2194.
43. Ohta Y, Tsuchihashi T, Arakawa K, Onaka U, Ueno M. Prevalence and lifestyle characteristics of hypertensive patients with metabolic syndrome followed at an outpatients clinic in Fukuoka, Japan. Hypertens Res 2007;30:1077-1082.
44. Fujita T. Insulin resistance and salt-sensitive hypertension in metabolic syndrome. Nephrol Dial Transplant 2007;22:3102-3107.